Wird geladen...
Strategies, Design, and Chemistry in siRNA Delivery Systems
Emerging therapeutics that utilize RNA interference (RNAi) have the potential to treat broad classes of diseases due to their ability to reversibly silence target genes. In August 2018, the FDA approved the first siRNA therapeutic, called ONPATTRO™ (Patisiran), for the treatment of transthyretin-med...
Gespeichert in:
| Veröffentlicht in: | Adv Drug Deliv Rev |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6745264/ https://ncbi.nlm.nih.gov/pubmed/31102606 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.addr.2019.05.004 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|